Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Average Rating of “Hold” from Brokerages

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have been given a consensus rating of “Hold” by the twelve analysts that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $61.90.

A number of analysts recently issued reports on HALO shares. Benchmark lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 7th. Morgan Stanley lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $73.00 to $62.00 in a research note on Wednesday, May 14th. JPMorgan Chase & Co. boosted their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the company a “neutral” rating in a research note on Monday, April 21st. Wells Fargo & Company boosted their target price on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 7th. Finally, Leerink Partners lowered shares of Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 target price for the company. in a research note on Tuesday, May 13th.

Insider Transactions at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $53.73, for a total value of $1,074,600.00. Following the completion of the transaction, the chief executive officer owned 733,719 shares in the company, valued at $39,422,721.87. This represents a 2.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Jeffrey William Henderson sold 4,497 shares of the stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $60.37, for a total transaction of $271,483.89. Following the completion of the transaction, the director owned 28,611 shares of the company’s stock, valued at $1,727,246.07. This represents a 13.58% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 44,497 shares of company stock valued at $2,405,284 in the last quarter. 2.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Isthmus Partners LLC lifted its holdings in Halozyme Therapeutics by 2.5% in the 1st quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company’s stock valued at $439,000 after acquiring an additional 169 shares during the last quarter. OneDigital Investment Advisors LLC lifted its holdings in Halozyme Therapeutics by 1.7% in the 1st quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company’s stock valued at $649,000 after acquiring an additional 175 shares during the last quarter. Park Place Capital Corp lifted its holdings in Halozyme Therapeutics by 20.1% in the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock valued at $69,000 after acquiring an additional 182 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 197 shares in the last quarter. Finally, Xponance Inc. boosted its holdings in shares of Halozyme Therapeutics by 1.1% in the first quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company’s stock worth $1,190,000 after buying an additional 198 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Trading Up 0.4%

NASDAQ HALO opened at $54.05 on Monday. Halozyme Therapeutics has a one year low of $42.01 and a one year high of $70.51. The company’s 50 day moving average price is $55.49 and its 200 day moving average price is $56.70. The company has a debt-to-equity ratio of 3.13, a quick ratio of 7.30 and a current ratio of 8.39. The firm has a market capitalization of $6.66 billion, a price-to-earnings ratio of 14.38, a PEG ratio of 0.36 and a beta of 1.15.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. The business had revenue of $264.86 million for the quarter, compared to analysts’ expectations of $231.21 million. During the same period in the previous year, the company posted $0.79 earnings per share. The business’s revenue for the quarter was up 35.2% compared to the same quarter last year. On average, sell-side analysts predict that Halozyme Therapeutics will post 4.73 EPS for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.